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Abstract
We conducted Myanmar-Japan cooperation studies on hepatitis B and hepatitis C virus mark-
ers in patients with thalassemias and those with liver diseases. Among the 102 patients with liver
diseases, 92% had a history of hepatitis B virus infection (antibody to hepatitis B core antigen pos-
itive), 35% were hepatitis B surface antigen positive, 39% were positive for anti-HCV. Among 28
patients with hepatocellular carcinoma, 46% had hepatitis B surface antigen, 21.4% had antibody
to hepatitis C virus, and 7% were positive for both hepatitis B surface antigen and anti hepatitis C
virus. The history of HCV infection among blood recipients at the Haematology Department of
the Yangon General Hospital and at the Yangon Children’s Hospital was found to be 55.5% and
46.7%, respectively, which is comparable to the history of hepatitis B infection (66.7% and 46.7%,
respectively). This preliminary survey also encountered 2 cases positive for anti-HCV among 34
voluntary blood donors. This survey is the first one to report that hepatitis C is at the epidemic
stage in Myanmar. As there is no effective treatment for hepatitis C in this country, a screening
program for blood used in transfusion should be started immediately.
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